Cash Position: Ended the quarter with $509 million in cash. Cash Burn: $118 million during Q1 2025, including cash operating expenses and capital expenditures. Cash Runway: Expected to extend into mid ...

Recursion Pharmaceuticals reported its second-quarter 2025 earnings with revenue significantly surpassing expectations, while earnings per share (EPS) fell short. The company posted an actual EPS of ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 7,175 calls trading, 1.0x expected, and implied vol increasing almost 2 points to 103.07%. Jan-26 10 calls and Jul-25 5.5 calls ...